Alzheimer’s disease (AD) is a complex and multifactorial neurodegenerative disease, which is currently diagnosed via clinical symptoms and nonspecific biomarkers (such as Aβ1–42, t-Tau, and p-Tau) ...

As part of its ongoing quest to redefine how people understand and address the brain's health and performance, the Center for ...

Serum S100A8/A9 levels are “significantly higher’ among patients with cognitive impairment in systemic lupus erythematosus, and changes in S100A8/A9 correspond to changes in cognition over 1 year, ...

The brain age gap (BAG) plays a role in mediating the influence of cognitive impairment risk factors on cognitive function, especially among individuals with high cerebrovascular disease (CeVD) burden ...

Traumatic Brain Injury (TBI) happens to millions of people annually. It can strike anyone, from athletes to grandma cooking lunch. Most of these injuries go und ...

Early detection of the stage of mild cognitive impairment (MCI) is very important for early diagnosis of dementia and slowing down the progression of Alzheimer's disease. Atrophy values obtained by ...

In the Phase 2 MINDFuL trial of XProTM in patients with early Alzheimer's Disease (AD) with biomarkers of inflammation, the modified intent-to-treat ...

Cognitive impairment in cardiac patients may interfere with disease management. This review describes studies examining specific cognitive impairments in cardiac patients and studies that investigate ...

The findings demonstrate how a 7-minute speech-based digital cognitive assessment from Linus Health captures quantifiable ...